Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Brand
I knew I’d read something about this and whilst it’s not an absolute correlation it is an interesting finding.
Particularly around NK killer cells
We observed that IFN-α treatment induced a significant decrease in CD4 T-cell counts (P < .0001), in CD4 T-cell–associated HIV-1 DNA copies (P = .002) and in HIV-1 DNA copies per microliter of blood (P < .0001) in our study patients. Notably, HIV-1 DNA levels were unrelated to HIV-1–specific CD8 T-cell responses. In contrast, proportions of total NK cells, CD56brightCD16– NK cells, and CD56brightCD16+ NK cells were significantly correlated with reduced levels of CD4 T-cell–associated HIV-1 DNA during IFN-α treatment, especially when coexpressing the activation markers NKG2D and NKp30.
Conclusions
These data suggest that the reduction of viral reservoir cells during treatment with IFN-α is primarily attributable to antiviral activities of NK cells.
For information
“IFNα and IFNβ share the same receptor and have very similar biological activities. Both confer resistance to viral infections on target cells”
https://academic.oup.com/cid/article/66/12/1910/4767848
Thanks Brand that a good article. I’ve read a number of articles that have mentioned this idea of viral reservoirs and long covid.
https://www.npr.org/sections/health-shots/2023/05/02/1172806898/why-viral-reservoirs-are-a-prime-suspect-for-long-covid-sleuths
I wonder if any of the activ2 patients had follow up on long covid symptoms and what if any analysis was done of blood plasma.
It would certainly be interesting to note if any Sprinter patients in the U.K. went on to get long covid and what if anything their blood plasma showed and whether they were placebo or drug patients?
Sorry Ghia but I can’t see your examples stand scrutiny
COPD
Sept 2017
Synairgen's strategy for its wholly-owned SNG001 programme is to progress into clinical development in COPD. The Company has therefore designed a short trial for the winter of 2017/18 to evaluate the potential of SNG001 in COPD, which is being submitted for regulatory approval.
They then said absolutely nothing about how things were progressing until 7th Feb 2018 when they announced first doing had started.
The idea that in the past they’ve provided regular updates before a trial has started doesn’t appear to be true.
Your examples Ghia seem to occur at best 4 weeks before a trial starts looking at Sprinter or Activ-2
Or during the trial
Sprinter or Active didn’t provide this information 5 months in advance of starting their trials
I was having a Quick Look at Avacta this morning to compare how happy investors are with the level of knowledge they have.
“Results in Q4 last year will be" data rich"...except, not so much. It’s now mid feb, and there is no confirmation if the 2 weekly dosing has started, I am not even sure if P1a has finished. No peer reviews, nothing to independently support AVCT's claims”
“Chris Coughlin mentioned they were already screening patients december 13 for arm 2. That is almost 2 months ago”
“By that comment you would assume it's full steam ahead. But as ever with Avacta who knows”
I hate to be a stickler for detail. I guess it comes fro my commercial background.
So when we say they’ve provided these details in the past on trials. Can you post an example
What was the information and what was date in relation to when the trial actually began?
You do not need to be a rocket scientist to know that the share price is roughly mirroring the company’s perceived cash balance. It will continue to do so with a a potential spike on trial news. However the drag on the share price will continue to be the positive sentiment for the p2 outcome vs the time and funding required to reach the next stage p3.
Time and funding will win over sentiment until that is clear
As an investor I always find looking at the companies investors page a useful place to visit
https://www.synairgen.com/investors
Might be worth reading page 4 Sept 2023 clinical update
https://synairgen.ams3.digitaloceanspaces.com/230921-Synairgen-Interims_FINAL.pdf
Have been traded today !
When the traders here can generate 20% of the shares traded in a drop. I’ll start to worry. Until then I’m just sitting patiently waiting for the trials to start along with TFG